Pharmacotherapy for Stimulant Use Disorders: A Systematic Review – NCBI Bookshelf
Stimulant use disorders, specifically cocaine and methamphetamine use, present ongoing public health problems in the United States, with major medical, psychiatric, cognitive, socioeconomic, and legal consequences. Source: Pharmacotherapy for Stimulant Use Disorders:...
read moreMeth on the rise in New Jersey
In August 2018, the DEA Intelligence Program, in conjunction with the NY/NJ High Intensity Drug Trafficking Area program and the NJ State Police Regional Operations Intelligence Center’s Drug Monitoring Initiative assessed the methamphetamine drug threat in New...
read moreMeth And Cocaine Are Spurring a “Fourth Wave” Of The Overdose Crisis
“It’s not your father’s drug market,” said one expert. “We have a synthetic drug crisis caused by stronger and more potent drugs.” Source: Meth And Cocaine Are Spurring a “Fourth Wave” Of The Overdose...
read moreBinding Methamphetamine to Release People from Addiction
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). We are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.
Pharmacotherapy for Stimulant Use Disorders: A Systematic Review – NCBI Bookshelf
Stimulant use disorders, specifically cocaine and methamphetamine use, present ongoing public health problems in the United States, with major medical, psychiatric, cognitive, socioeconomic, and legal consequences. Source: Pharmacotherapy for Stimulant Use Disorders:...
read moreMeth on the rise in New Jersey
In August 2018, the DEA Intelligence Program, in conjunction with the NY/NJ High Intensity Drug Trafficking Area program and the NJ State Police Regional Operations Intelligence Center’s Drug Monitoring Initiative assessed the methamphetamine drug threat in New...
read moreMeth And Cocaine Are Spurring a “Fourth Wave” Of The Overdose Crisis
“It’s not your father’s drug market,” said one expert. “We have a synthetic drug crisis caused by stronger and more potent drugs.” Source: Meth And Cocaine Are Spurring a “Fourth Wave” Of The Overdose...
read moreDeveloping Novel Therapeutics for Addiction
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 is being studied in an upcoming Phase 2 proof-of-concept study (STAMPOUT). We are also developing a novel vaccine (IXT-v100) against methamphetamine.